Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:morgag04

Total Results:

677


Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma

Caro, Jessica; Cairns, David; Menzies, Tom; Boyle, Eileen; Pawlyn, Charlotte; Cook, Gordon; Kaiser, Martin; Walker, Brian A; Owen, Roger; Jackson, Graham H; Morgan, Gareth J; Heaney, Jennifer; Drayson, Mark T; Davies, Faith E
INTRODUCTION/BACKGROUND/BACKGROUND:Immunoparesis, or low polyclonal immunoglobulin levels, is commonly seen in multiple myeloma (MM), and is associated with poor clinical outcomes. MM can be divided into subgroups with distinct biology and outcomes based on etiologic cytogenetic abnormalities. These include hyperdiploidy and translocations of t(11;14), t(4;14), t(14;16), and t(14;20), with the latter 3 associated with high-risk disease. We hypothesized that the different etiologic cytogenetic abnormalities drive bone marrow microenvironmental changes, resulting in different degrees of immunoparesis, and subgroup-dependent effects on clinical outcomes. MATERIALS AND METHODS/METHODS:We performed a retrospective review of 985 newly diagnosed patients enrolled in the Myeloma IX and XI trials. Immunoglobulin levels, survival outcomes, and infection rates were evaluated for each cytogenetic subgroup. RESULTS:A significant proportion of patients with high-risk t(4;14), t(14;16), or t(14;20) had suppressed polyclonal immunoglobulins compared to standard-risk patients with hyperdiploidy or t(11;14). The clinical impact of immunoparesis depended on the cytogenetic subgroup, with the degree of IgM suppression effecting progression-free and overall survival only in the hyperdiploid subgroup. There was no significant difference in infection rates amongst the etiologic subgroups. CONCLUSION/CONCLUSIONS:These findings demonstrate that the etiologic cytogenetic subgroup influences the degree and clinical impact of immunoparesis. This suggests that the underlying cytogenetic abnormality affects remodeling of the bone marrow plasma cell niche, resulting in suppressed normal plasma cell function, and low immunoglobulin levels.
PMID: 34876373
ISSN: 2152-2669
CID: 5110212

Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups

Boyle, Eileen M; Rosenthal, Adam; Ghamlouch, Hussein; Wang, Yan; Farmer, Phillip; Rutherford, Michael; Ashby, Cody; Bauer, Michael; Johnson, Sarah K; Wardell, Christopher P; Wang, Yubao; Hoering, Antje; Schinke, Carolina; Thanendrarajan, Sharmilan; Zangari, Maurizio; Barlogie, Bart; Dhodapkar, Madhav V; Davies, Faith E; Morgan, Gareth J; van Rhee, Frits; Walker, Brian A
Sequencing studies have shed some light on the pathogenesis of progression from smouldering multiple myeloma (SMM) and symptomatic multiple myeloma (MM). Given the scarcity of smouldering samples, little data are available to determine which translational programmes are dysregulated and whether the mechanisms of progression are uniform across the main molecular subgroups. In this work, we investigated 223 SMM and 1348 MM samples from the University of Arkansas for Medical Sciences (UAMS) for which we had gene expression profiling (GEP). Patients were analysed by TC-7 subgroup for gene expression changes between SMM and MM. Among the commonly dysregulated genes in each subgroup, PHF19 and EZH2 highlight the importance of the PRC2.1 complex. We show that subgroup specific differences exist even at the SMM stage of disease with different biological features driving progression within each TC molecular subgroup. These data suggest that MMSET SMM has already transformed, but that the other precursor diseases are distinct clinical entities from their symptomatic counterpart.
PMID: 34365473
ISSN: 1476-5551
CID: 5006072

Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length

Boyle, Eileen M; Williams, Louis; Blaney, Patrick; Ashby, Cody; Bauer, Michael; Walker, Brian A; Ghamlouch, Hussein; Choi, Jinyoung; Perrial, Emeline; Wang, Yubao; Caro, Jessica; Stoeckle, James H; Arbini, Arnaldo; Kaminetzky, David; Braunstein, Marc; Bruno, Benedetto; Razzo, Beatrice; Diamond, Benjamin; Maclachlan, Kylee; Maura, Francesco; Landgren, Ola; Litke, Rachel; Fegan, Christopher D; Keats, Johnathan; Auclair, Daniel; Davies, Faith E; Morgan, Gareth J
PMID: 34148053
ISSN: 1476-5551
CID: 4918002

Chromothripsis as a pathogenic driver of multiple myeloma

Maura, Francesco; Boyle, Eileen M; Rustad, Even H; Ashby, Cody; Kaminetzky, David; Bruno, Benedetto; Braunstein, Marc; Bauer, Michael; Blaney, Patrick; Wang, Yubao; Ghamlouch, Hussein; Williams, Louis; Stoeckle, James; Davies, Faith E; Walker, Brian A; Maclachlan, Kylee; Diamond, Ben; Landgren, Ola; Morgan, Gareth J
Analysis of the genetic basis for multiple myeloma (MM) has informed many of our current concepts of the biology that underlies disease initiation and progression. Studying these events in further detail is predicted to deliver important insights into its pathogenesis, prognosis and treatment. Information from whole genome sequencing of structural variation is revealing the role of these events as drivers of MM. In particular, we discuss how the insights we have gained from studying chromothripsis suggest that it can be used to provide information on disease initiation and that, as a consequence, it can be used for the clinical classification of myeloma precursor diseases allowing for early intervention and prognostic determination. For newly diagnosed MM, the integration of information on the presence of chromothripsis has the potential to significantly enhance current risk prediction strategies and to better characterize patients with high-risk disease biology. In this article we summarize the genetic basis for MM and the role played by chromothripsis as a critical pathogenic factor active at early disease phases.
PMID: 33958284
ISSN: 1096-3634
CID: 4866742

Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpassstudy [Meeting Abstract]

Williams, Louis; Blaney, Patrick; Boyle, Eileen M.; Ghamlouch, Hussein; Wang, Yubao; Choi, Jinyoung; Bauer, Michael A.; Siegel, Ariel; Stoeckle, James; Razzo, Beatrice; Auclair, Daniel; Kaminetzky, David; Braunstein, Marc; Bruno, Benedetto; Arbini, Arnaldo A.; Walker, Brian A.; Davies, Faith E.; Morgan, Gareth J.
ISI:000835740100118
ISSN: 0006-4971
CID: 5389192

Unifying the Definition of High-Risk in Multiple Myeloma [Meeting Abstract]

Siegel, Ariel; Boyle, Eileen M.; Blaney, Patrick; Wang, Yubao; Ghamlouch, Hussein; Choi, Jinyoung; Caro, Jessica; Williams, Louis; Razzo, Beatrice; Arbini, Arnaldo A.; Braunstein, Marc; Kaminetzky, David; Auclair, Daniel; Pawlyn, Charlotte; Cairns, David; Jackson, Graham; Walker, Brian; Bruno, Benedetto; Morgan, Gareth J.; Davies, Faith E.
ISI:000736413903013
ISSN: 0006-4971
CID: 5389182

Multiomic Mapping of Copy Number and Structural Variation on Chromosome 1 (Chr1) Highlights Multiple Recurrent Disease Drivers [Meeting Abstract]

Blaney, Patrick; Boyle, Eileen M.; Wang, Yubao; Ghamlouch, Hussein; Choi, Jinyoung; Williams, Louis; James, Stoeckle; Siegel, Ariel; Razzo, Beatrice; Braunstein, Marc; Kaminetzky, David; Arbini, Arnaldo A.; Bruno, Benedetto; Corre, Jill; Montes, Lydia; Auclair, Daniel; Davies, Faith E.; Tsirigos, Aristotelis; Rustad, Even H.; Maura, Francesco; Landgren, Ola; Bauer, Michael A.; Walker, Brian; Morgan, Gareth
ISI:000736398803021
ISSN: 0006-4971
CID: 5389172

Improving prognostic assignment in older age groups of multiple myeloma [Meeting Abstract]

Boyle, E. M.; Litke, R. R.; Blaney, P.; Ashby, T. C.; Bauer, M.; Walker, B.; Ghamlouch, H.; Choi, J.; Perrial, E.; Wang, Y.; Caro, J.; Stoeckle, J.; Arbini, A.; Kaminetsky, D.; Braunstein, M.; Bruno, B.; Razzo, B.; Maclachlan, K.; Maura, E.; Landgren, C. O.; Williams, L.; Fegan, C.; Keats, J.; Davies, F. E.; Morgan, G. J.
ISI:000635723900566
ISSN: 0002-8614
CID: 5389142

The evolving role and utility of off-label drug use in multiple myeloma

Stoeckle, James H; Davies, Faith E; Williams, Louis; Boyle, Eileen M; Morgan, Gareth J
The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 19 drug approvals and at least eight different active classes. The advances seen in MM therapy have relied on both a structured approach to obtaining new labels and cautious off-label drug use. Although there are country and regional differences in drug approval processes, many of the basic principles behind off-label drug use in MM can be summarized into four main categories: 1) use of a therapy prior to the current approval regulations; 2) widespread use of a therapy following the release of promising clinical trial results but prior to drug approval; 3) use of a cheap therapy supported by clinical safety and efficacy data but without commercial backing; and 4) niche therapies for small well-defined patient populations where large clinical trials with sufficient power may be difficult to perform. This review takes a historical approach to discuss how off-label drug use has helped to shape the current treatment approach for MM.
PMCID:9400732
PMID: 36046752
ISSN: 2692-3114
CID: 5387612

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies [Meeting Abstract]

Chng, W -J; Lonial, S; Morgan, G J; Iida, S; Moreau, P; Kumar, S; Twumasi-Ankrah, P; Kumar, A; Dash, A B; Vorog, A; Zhang, X; Suryanarayan, K; Labotka, R; Dimopoulos, M A; Rajkumar, S V
Introduction: A number of cytogenetic abnormalities (CAs) are associated with poorer prognosis in MM, including del(17p), t(4;14), t(14;16), and amp1q21. There is a general consensus that treatment with proteasome inhibitors (PIs) benefits pts carrying these CAs (Sonneveld Blood 2016). This meta-analysis of four phase 3 studies assesses PFS benefit in pts receiving the oral PI ixa vs pbo regarding the specific adverse CAs.
Method(s): Pts in TOURMALINE-MM1 (N=722; relapsed/refractory MM; Moreau N Engl J Med 2016) and MM2 (N=705; newly diagnosed MM; Facon Blood 2021) received ixa plus lenalidomide-dexamethasone (Rd) vs pbo-Rd (1:1). Pts in TOURMALINE-MM3 (N=656; Dimopoulos Lancet 2019) and TOURMALINE-MM4 (N=706; Dimopoulos J Clin Oncol 2020) received ixa vs pbo (3:2) as maintenance following autologous stem cell transplant or as post-induction maintenance in transplant-ineligible pts, respectively. In TOURMALINE-MM1/MM2, CAs were centrally assessed on CD138 positive sorted cells from bone marrow samples collected at study entry using fluorescence in situ hybridization (FISH). Cutoff values for defining the presence of del(17p), t(4;14), and t(14;16) were 5%, 3%, and 3% positive cells, respectively, based on the false-positive rates (technical cutoffs) of the FISH probes used, and cutoff values of 3% (MM1) and 20% (MM2) were used for amp1q21. In TOURMALINE-MM3/MM4, cytogenetic assessment was performed locally using FISH or conventional karyotyping with locally defined thresholds for positivity.
Result(s): 270/1227 (22%) vs 227/1019 (22%) evaluable pts receiving ixa-based vs pbo-based therapy had high-risk CAs [del(17p), t(4;14), t(14;16)]: 75 vs 62 in MM1, 60 vs 63 in MM2, 61 vs 54 in MM3, and 74 vs 48 in MM4. 957/1227 (78%) vs 792/1019 (78%) had complementary standard-risk CAs: 200 vs 216 in MM1, 231 vs 234 in MM2, 252 vs 152 in MM3, and 275 vs 190 in MM4. 555/1142 (49%) vs 479/955 (50%) evaluable pts receiving ixa-based vs pbo-based therapy had expanded high-risk CAs (high-risk CAs +/- amp1q21): 155 vs 154 in MM1, 134 vs 146 in MM2, 116 vs 88 in MM3, and 150 vs 91 in MM4. 587/1142 (51%) vs 476/955 (50%) had complementary standard-risk CAs: 122 vs 126 in MM1, 164 vs 153 in MM2, 154 vs 89 in MM3, and 148 vs 108 in MM4. After a median follow-up in the pooled analysis of 25.6 months (mos; 12.7, 54.6, 29.7, and 21.3 mos in MM1, MM2, MM3, and MM4, respectively), the hazard ratio (HR) for PFS with ixa-based vs pbo-based therapy in pts with high-risk CAs was 0.74 (95% confidence interval [CI] 0.59-0.93; median 17.8 vs 13.2 mos) and 0.70, (95% CI 0.62-0.80; median 26.3 vs 17.6 mos) in pts with standard-risk CAs. In the subgroup analyses of expanded high-risk CAs, the HR for PFS with ixa-based vs pbo-based therapy in pts in the expanded high-risk group was 0.75 (95% CI 0.64-0.87; median 18.1 vs 14.1 mos; Figure 1) and 0.71 (95% CI 0.59-0.85; median 36.1 vs 21.4 mos) in the complementary standard-risk group. Analyses of PFS according to the presence of individual CAs (Figure 2) indicated differing magnitudes of PFS benefit. Notably, in pts with t(4;14) (n=124 vs n=102), the HR for PFS with ixa-based vs pbo-based therapy was 0.68 (95% CI 0.48-0.96; median 22.4 vs 13.2 mos), while for pts with amp1q21 (n=380 vs n=312), the HR was 0.77 (95% CI 0.63-0.93; median 18.8 vs 14.5 mos) and for pts with del(17p) (n=141 vs n=107) the HR was 0.80 (95% CI 0.59-1.09; median 15.7 vs 13.2 mos).
Conclusion(s): This pooled analysis demonstrated a PFS benefit with ixa-based therapy vs pbo-based therapy regardless of the presence of specific adverse CAs, with a similar magnitude of benefit in pts with (expanded) high-risk CAs and the respective complementary standard-risk groups. However, due to the differences in study eligibility criteria and pt populations, ixa combined with Rd or as single-agent maintenance therapy may not abrogate the negative impact of high-risk CAs. Analyses of PFS in subgroups with specific CAs indicated that the greatest magnitudes of benefit (lowest HRs) with ixa-based vs pbo-based therapy were in pts with t(4;14) (HR 0.68) and pts with amp1q21 (HR 0.77), suggesting that the improved outcome with ixa-based vs pbo-based therapy in the expanded high-risk subgroup was primarily driven by PFS differences in pts with these more common CAs. Further study is needed, and additional sensitivity analyses will be presented in subsequent publications. [Formula presented] Disclosures: Chng: BMS/Celgene: Honoraria, Research Funding; Amgen: Honoraria; Takeda: Honoraria; Abbvie: Honoraria; Sanofi: Honoraria; Pfizer: Honoraria; Johnson and Johnson: Honoraria, Research Funding. Lonial: BMS/Celgene: Consultancy, Honoraria, Research Funding; AMGEN: Consultancy, Honoraria; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Merck: Honoraria. Morgan: Takeda: Honoraria. Iida: Amgen: Research Funding; Daiichi Sankyo: Research Funding; Glaxo SmithKlein: Research Funding; Ono: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Chugai: Research Funding; Abbvie: Research Funding; Janssen: Honoraria, Research Funding; Bristol-Myers Squibb: Research Funding. Moreau: Sanofi: Honoraria; Celgene BMS: Honoraria; Abbvie: Honoraria; Amgen: Honoraria; Janssen: Honoraria; Oncopeptides: Honoraria. Kumar: Bluebird Bio: Consultancy; Carsgen: Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Antengene: Consultancy, Honoraria; Novartis: Research Funding; Oncopeptides: Consultancy; Tenebio: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche-Genentech: Consultancy, Research Funding; Beigene: Consultancy; Merck: Research Funding; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding. Twumasi-Ankrah: Takeda: Current Employment. Kumar: Takeda: Current Employment, Current holder of stock options in a privately-held company. Dash: Takeda: Current Employment, Current equity holder in publicly-traded company. Vorog: Takeda: Current Employment. Zhang: Takeda: Current Employment. Suryanarayan: Takeda: Current Employment. Labotka: Takeda: Current Employment. Dimopoulos: Janssen: Honoraria; Takeda: Honoraria; Beigene: Honoraria; BMS: Honoraria; Amgen: Honoraria. OffLabel Disclosure: Use of the oral proteasome inhibitor ixazomib for the initial treatment of multiple myeloma and as maintenance treatment following stem cell transplantation or induction therapy in newly diagnosed patients
Copyright
EMBASE:2016087438
ISSN: 1528-0020
CID: 5184092